MAAT INDEX

CLAIM #56627 · Thermo Fisher Scientific Inc (TMO) · 2026Q1 earnings call · Apr 23, 2026 · due Dec 31, 2026

We expect approximately $660 million of net interest expense, which now includes financing for the Clario acquisition.

James Meyer · CFO

PENDING
graded after results covering Dec 31, 2026 are reported

How to check this claim

Look at: Full-year net interest expense, fiscal 2026

It came true if: Net interest expense between $630 million and $690 million (within ~5% of $660 million)

Where: Company income statement / 10-K or Q4 2026 earnings release

In context

creased our 2026 revenue guidance by $900 million and added $0.32 of adjusted EPS net of financing costs. At the midpoint, the increase in adjusted EPS reflects the contribution from Clario and the strong operational performance in Q1, partially offset by an assumption for higher inflation in future quarters that we are actively working to mitigate. In terms of adjusted operating margins, our guide has increased to 70 basis points of expansion for the year, including the addition of Clario and the strong performance we delivered in Q1. We are continuing to actively manage the company and drive excellent operational performance, enabling us to increase our guidance for the year while navigating a complex macro environment. Let me provide you some of the modeling elements for the full year. We expect approximately $660 million of net interest expense, which now includes financing for the Clario acquisition. We continue to assume that the adjusted income tax rate will be 11.5%. We expect between $1.9 billion and $2.1 billion of net capital expenditures and free cash flow in the range of $6.9 billion to $7.4 billion for the year, both reflecting the addition of Clario. In terms of capital deployment, we're assuming $3 billion of share buybacks, which were already completed in January and that we'll return approximately $700 million of capital to shareholders this year through dividends. We estimate the full year average diluted share count will be between $370 million and 375 million shares. Now let me provide some color on phasing for Q2. Aligned with the quarterly progression in our original guidance, we are assuming organic revenue growth of about 3% for the second quarter. We expect Q2 adj

Verify independently

SEC filings for TMO · Claim quote is verbatim from the 2026Q1 earnings call.